Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease

NCT02214121 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02214121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02214121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2014
Completion date
February 27, 2017
Enrollment
46 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

investigation of platelet aggregation in paediatric patients with sickle cell disease